Gruss E.
chart.bigcharts.com/bc3/quickchart/...62&mocktick=1&rand=8383"
chart.bigcharts.com/bc3/quickchart/...10&mocktick=1&rand=5735"
Top-News
Visionen mit LCA Vision und TLC Vision
Beiträge:
14
Zugriffe: 774 / Heute: 2
Zugriffe: 774 / Heute: 2
Gruss E.
chart.bigcharts.com/bc3/quickchart/...51&mocktick=1&rand=7187"
Vision Sciences(R) Receives FDA Clearance for New EndoSheath(R) Product for In-Office Diagnosis of Acid Reflux Disease
FRIDAY, JULY 18, 2003 7:02 AM
- PR Newswire
NATICK, Mass., Jul 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Vision-Sciences, Inc., (VSCI) today announced that it has received clearance to market its new Slide-On(TM) EndoSheath(R) System for Sensory Testing used in conjunction with flexible ENT (Ear, Nose and Throat) endoscopes from the US Food and Drug Administration (FDA).
The Slide-On EndoSheath System for Sensory Testing is an alternative to a modified barium swallowing study that eliminates the need for fluoroscopy and exposure to X-rays, and can be performed as an office procedure. The exam is used to help diagnose acid reflux disease and swallowing disorders that could lead to aspiration pneumonia. It is estimated that 40 million people in the United States suffer from some form of acid reflux disease affecting a portion of the vocal cords, esophagus and/or stomach.
Ron Hadani, President and CEO of Vision Sciences, stated that "This innovative product offers otolaryngologists, gastroenterologists, pulmonologists and speech pathologists the simplest and most economical way to perform sensory testing as it eliminates the required purchase of an additional specialized endoscope. The Sensory Sheath expands the use of the large installed base of diagnostic ENT scopes as it slides directly onto all the commonly used models and provides the required air channel. The sensory test procedure is performed in the physician's office by introducing small puffs of air that are passed through the sheath. The air puffs elicit a reflex response from the vocal cords, and provide diagnostic information useful in the detection of acid reflux disease and swallowing disorders."
Michael Setzen, M.D., F.A.C.S., an Otolaryngologist in private practice in Manhasset, NY and former Chair of the Board of Governors for the American Academy of Otolaryngology-Head and Neck Surgery, stated that "Problems related to swallowing and reflux have become a significant issue in medicine today and treating these conditions is a major part of the average Otolaryngologist's practice."
Setzen also stated that "Flexible Endoscopic Evaluation of Swallowing with Sensory Testing (FEESST) is a dynamic evaluation of swallowing with testing of sensation, usually performed in an office setting with a flexible endoscope and does not require the use of x-rays. The use of a single-use sheath allows for the safe and efficient passage of a flexible endoscope without requiring lengthy cleaning procedures and the use of chemical disinfectants that may cause irritation."
V. Alin Botoman, M.D., former Chairman of Gastroenterology at the Cleveland Clinic Florida, and currently Clinical Associate Professor at the University of Miami in Florida states, "We found that when we added laryngopharyngeal sensory testing to transnasal flexible laryngoscopy it improved the accuracy of flexible laryngoscopy for diagnosing patients with proximal GERD (Gastro-Esophageal Reflux Disease). Gastroesophageal related pharyngeal complaints are one of the most common reasons patients see Otolaryngologists. This product is a potentially exciting low cost means of expanding the diagnostic armamentaria for functional pharyngeal symptoms for practicing physicians."
The technology for this product was developed by Vision Sciences. The FEESST procedure was developed at the College of Physicians and Surgeons of Columbia University.
Vision-Sciences, Inc. develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths, the Slide-On(TM) EndoSheath(R) System, which provide the users quick, efficient product turnover while ensuring the patient a contaminant-free product. Information about Vision Sciences products is available on the Internet at www.EndoSheath.com, and Company information is available at www.visionsciences.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements for the purposes of the safe harbor protections under The Private Securities Litigation Reform Act of 1995. Future results may vary significantly based on a number of factors including, but not limited to, the availability of capital resources, risks in market acceptance of new products and services and continuing demand for same, the impact of competitive products and pricing, seasonality, changing economic conditions and other risk factors detailed in our most recent annual report and other filings with the SEC. In addition, forward-looking statements represent our estimates only as of today, and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
Contact:
Gerald B. Lichtenberger
V.P. of Business Development
Tel: (845) 365-0600
SOURCE Vision-Sciences, Inc.
Und die Zahlen von heute:
Vision Sciences Reports First Quarter Results
WEDNESDAY, JULY 23, 2003 7:02 AM
- PR Newswire
NATICK, Mass., Jul 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Vision-Sciences, Inc., (VSCI) today announced results for its fiscal quarter ended June 30, 2003. For the first quarter of fiscal 2004, revenues increased by 13% to $1.96 million, compared to $1.73 million in the three months ended June 30, 2002. The net loss for the quarter was $0.3 million, or $0.01 per share, compared to $0.3 million, or $0.01 per share last year. Full results for the first fiscal quarter will be reported in the Company's Quarterly Report on Form 10-Q, expected to be filed with the SEC by August 14, 2003.
In the first fiscal quarter, sales of the medical segment were approximately $1.27 million, an increase of $0.26 million, or 26%, compared to the same quarter last year. Sales of the industrial segment were approximately $0.69 million, a decrease of $0.04 million, or 5%, compared to the same quarter last year. The increase in sales of the medical segment was primarily due to a higher volume of EndoSheath(R) Systems sold to the domestic and international Ear-Nose-Throat ("ENT") market. The decrease in sales of the industrial segment was primarily due to lower volume from the aircraft engine market stemming from continued slowness in air travel.
The unit volume of ENT sheaths increased by 39% in the quarter ended June 30, 2003, compared to the same quarter last year, improving in the domestic and international markets, by 10% and 58%, respectively. In the domestic market, the Company has continued both an incentive program for new customers and an emphasis on the practice efficiencies of the ENT EndoSheath. Both marketing strategies contributed significantly to the increase in unit shipments. In the international market, the Company continues to experience consistently growing demand for its products.
"We are pleased with the increase in unit volume of ENT sheaths, and the improved gross profit of the medical segment, which we believe is a direct result of the improvements in our sales and marketing capabilities, the improvement in our production processes and the on-going drive for product cost reduction," stated Ron Hadani, President and CEO. "The improved gross profit and our continued expense control resulted in the medical segment recording an operating profit of approximately $24,000 for the quarter. Our goal is to build on this success for the remainder of fiscal 2004."
Vision-Sciences, Inc. develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths, the Slide-On(TM) EndoSheath(R) System, which provide the users quick, efficient product turnover while ensuring the patient a contaminant-free product. Information about Vision Sciences products is available on the Internet at www.EndoSheath.com, and company information is available at www.visionsciences.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements for the purposes of the safe harbor protections under The Private Securities Litigation Reform Act of 1995. Future results may vary significantly based on a number of factors including, but not limited to, the availability of capital resources, risks in market acceptance of new products and services and continuing demand for same, the impact of competitive products and pricing, seasonality, changing economic conditions and other risk factors detailed in our most recent annual report and other filings with the SEC. In addition, forward-looking statements represent our estimates only as of today, and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
Contact:
Gerald B. Lichtenberger
V.P. of Business Development
Tel: (845) 365-0600
SOURCE Vision-Sciences, Inc.
Gerald B. Lichtenberger, V.P. of Business Development for
Vision-Sciences, Inc., +1-845-365-0600
Vision Sciences(R) Receives FDA Clearance for New EndoSheath(R) Product for In-Office Diagnosis of Acid Reflux Disease
FRIDAY, JULY 18, 2003 7:02 AM
- PR Newswire
NATICK, Mass., Jul 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Vision-Sciences, Inc., (VSCI) today announced that it has received clearance to market its new Slide-On(TM) EndoSheath(R) System for Sensory Testing used in conjunction with flexible ENT (Ear, Nose and Throat) endoscopes from the US Food and Drug Administration (FDA).
The Slide-On EndoSheath System for Sensory Testing is an alternative to a modified barium swallowing study that eliminates the need for fluoroscopy and exposure to X-rays, and can be performed as an office procedure. The exam is used to help diagnose acid reflux disease and swallowing disorders that could lead to aspiration pneumonia. It is estimated that 40 million people in the United States suffer from some form of acid reflux disease affecting a portion of the vocal cords, esophagus and/or stomach.
Ron Hadani, President and CEO of Vision Sciences, stated that "This innovative product offers otolaryngologists, gastroenterologists, pulmonologists and speech pathologists the simplest and most economical way to perform sensory testing as it eliminates the required purchase of an additional specialized endoscope. The Sensory Sheath expands the use of the large installed base of diagnostic ENT scopes as it slides directly onto all the commonly used models and provides the required air channel. The sensory test procedure is performed in the physician's office by introducing small puffs of air that are passed through the sheath. The air puffs elicit a reflex response from the vocal cords, and provide diagnostic information useful in the detection of acid reflux disease and swallowing disorders."
Michael Setzen, M.D., F.A.C.S., an Otolaryngologist in private practice in Manhasset, NY and former Chair of the Board of Governors for the American Academy of Otolaryngology-Head and Neck Surgery, stated that "Problems related to swallowing and reflux have become a significant issue in medicine today and treating these conditions is a major part of the average Otolaryngologist's practice."
Setzen also stated that "Flexible Endoscopic Evaluation of Swallowing with Sensory Testing (FEESST) is a dynamic evaluation of swallowing with testing of sensation, usually performed in an office setting with a flexible endoscope and does not require the use of x-rays. The use of a single-use sheath allows for the safe and efficient passage of a flexible endoscope without requiring lengthy cleaning procedures and the use of chemical disinfectants that may cause irritation."
V. Alin Botoman, M.D., former Chairman of Gastroenterology at the Cleveland Clinic Florida, and currently Clinical Associate Professor at the University of Miami in Florida states, "We found that when we added laryngopharyngeal sensory testing to transnasal flexible laryngoscopy it improved the accuracy of flexible laryngoscopy for diagnosing patients with proximal GERD (Gastro-Esophageal Reflux Disease). Gastroesophageal related pharyngeal complaints are one of the most common reasons patients see Otolaryngologists. This product is a potentially exciting low cost means of expanding the diagnostic armamentaria for functional pharyngeal symptoms for practicing physicians."
The technology for this product was developed by Vision Sciences. The FEESST procedure was developed at the College of Physicians and Surgeons of Columbia University.
Vision-Sciences, Inc. develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths, the Slide-On(TM) EndoSheath(R) System, which provide the users quick, efficient product turnover while ensuring the patient a contaminant-free product. Information about Vision Sciences products is available on the Internet at www.EndoSheath.com, and Company information is available at www.visionsciences.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements for the purposes of the safe harbor protections under The Private Securities Litigation Reform Act of 1995. Future results may vary significantly based on a number of factors including, but not limited to, the availability of capital resources, risks in market acceptance of new products and services and continuing demand for same, the impact of competitive products and pricing, seasonality, changing economic conditions and other risk factors detailed in our most recent annual report and other filings with the SEC. In addition, forward-looking statements represent our estimates only as of today, and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
Contact:
Gerald B. Lichtenberger
V.P. of Business Development
Tel: (845) 365-0600
SOURCE Vision-Sciences, Inc.
Und die Zahlen von heute:
Vision Sciences Reports First Quarter Results
WEDNESDAY, JULY 23, 2003 7:02 AM
- PR Newswire
NATICK, Mass., Jul 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Vision-Sciences, Inc., (VSCI) today announced results for its fiscal quarter ended June 30, 2003. For the first quarter of fiscal 2004, revenues increased by 13% to $1.96 million, compared to $1.73 million in the three months ended June 30, 2002. The net loss for the quarter was $0.3 million, or $0.01 per share, compared to $0.3 million, or $0.01 per share last year. Full results for the first fiscal quarter will be reported in the Company's Quarterly Report on Form 10-Q, expected to be filed with the SEC by August 14, 2003.
In the first fiscal quarter, sales of the medical segment were approximately $1.27 million, an increase of $0.26 million, or 26%, compared to the same quarter last year. Sales of the industrial segment were approximately $0.69 million, a decrease of $0.04 million, or 5%, compared to the same quarter last year. The increase in sales of the medical segment was primarily due to a higher volume of EndoSheath(R) Systems sold to the domestic and international Ear-Nose-Throat ("ENT") market. The decrease in sales of the industrial segment was primarily due to lower volume from the aircraft engine market stemming from continued slowness in air travel.
The unit volume of ENT sheaths increased by 39% in the quarter ended June 30, 2003, compared to the same quarter last year, improving in the domestic and international markets, by 10% and 58%, respectively. In the domestic market, the Company has continued both an incentive program for new customers and an emphasis on the practice efficiencies of the ENT EndoSheath. Both marketing strategies contributed significantly to the increase in unit shipments. In the international market, the Company continues to experience consistently growing demand for its products.
"We are pleased with the increase in unit volume of ENT sheaths, and the improved gross profit of the medical segment, which we believe is a direct result of the improvements in our sales and marketing capabilities, the improvement in our production processes and the on-going drive for product cost reduction," stated Ron Hadani, President and CEO. "The improved gross profit and our continued expense control resulted in the medical segment recording an operating profit of approximately $24,000 for the quarter. Our goal is to build on this success for the remainder of fiscal 2004."
Vision-Sciences, Inc. develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths, the Slide-On(TM) EndoSheath(R) System, which provide the users quick, efficient product turnover while ensuring the patient a contaminant-free product. Information about Vision Sciences products is available on the Internet at www.EndoSheath.com, and company information is available at www.visionsciences.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements for the purposes of the safe harbor protections under The Private Securities Litigation Reform Act of 1995. Future results may vary significantly based on a number of factors including, but not limited to, the availability of capital resources, risks in market acceptance of new products and services and continuing demand for same, the impact of competitive products and pricing, seasonality, changing economic conditions and other risk factors detailed in our most recent annual report and other filings with the SEC. In addition, forward-looking statements represent our estimates only as of today, and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
Contact:
Gerald B. Lichtenberger
V.P. of Business Development
Tel: (845) 365-0600
SOURCE Vision-Sciences, Inc.
Gerald B. Lichtenberger, V.P. of Business Development for
Vision-Sciences, Inc., +1-845-365-0600
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
s umgesetzt. Das ist ordentlich.
Ehrlich gesagt, kannte ich diese Shares gar nicht, bin nicht investiert und nur bei der Marktübersicht drauf gestossen.
Jetzt werden diese Shares nicht mehr aus den Augen gelassen.
Und tschüss für heute.
Gruss E.
Ehrlich gesagt, kannte ich diese Shares gar nicht, bin nicht investiert und nur bei der Marktübersicht drauf gestossen.
Jetzt werden diese Shares nicht mehr aus den Augen gelassen.
Und tschüss für heute.
Gruss E.
Eskimato für die Tipps. Werde sie auf meine WL setzen und in 3 Wochen ärgern, daß ich sie nicht gekauft habe.
SNDK läuft nach Minikonsolidierung schön weiter und CHINA wird nach 30% Korrektur auch wieder interessant.
Viele Grüße,
bellfounder
SNDK läuft nach Minikonsolidierung schön weiter und CHINA wird nach 30% Korrektur auch wieder interessant.
Viele Grüße,
bellfounder
Als absoluter Börsenneuling und Abonnent des Cutting Edge-Börsenbriefs - es muss irgendwann Anfang 2000 gewesen sein - beschloss ich auf deren Empfehlung hin ein paar Aktien zu kaufen. Meistens musste man damals schnell ordern, da die hier in D ein paar Abonnenten mehr hatten und alleine durch deren Empfehlung stiegen die Dinger, die sonst fast nie über Frankfurt gehandelt wurden, gleich in den ersten Minuten rapide. Wenn dann in Amerika nichts nachkam, konnte man sehen, wie man den Scheiß wieder los wurde, da sich der Kurs natürlich im Endeffekt nach den US-Kursen richtete.
In der Hektik verrutschte mir leider die Kommastelle und ich orderte 10mal soviel wie geplant. Glücklicherweise war es auch die letzte TAN-Nummer und telefonisch ging irgendwie auch nichts. Ich glaube damals war 17 Uhr Ende bei der Comdirect.
Es kam wie es kommen musste - der Kurs schmierte ab.
Eine lehrreiche Erfahrung :-)
In der Hektik verrutschte mir leider die Kommastelle und ich orderte 10mal soviel wie geplant. Glücklicherweise war es auch die letzte TAN-Nummer und telefonisch ging irgendwie auch nichts. Ich glaube damals war 17 Uhr Ende bei der Comdirect.
Es kam wie es kommen musste - der Kurs schmierte ab.
Eine lehrreiche Erfahrung :-)
das liest sich ja wie eine Horrorgeschichte. Ähnliche Mißgeschicke habe ich aber auch erlebt. War vor ein paar Monaten mit Mobilcom. Da hab ich am Nachmittag noch mal nachgelegt, blieb vor dem Rechner sitzen und wollte sehen, wie sich der Kurs entwickelt. Als ich dann etliche Prozente im Plus war und die Aktie begann, abzuschmieren konnte ich nicht verkaufen. Intraday ist nämlich nicht beim normalen SEB-Depot. Das habe ich dann nach einigen sehr hektischen Telefonaten mit der Bank erfahren. Also mußte ich zusehen, wie die schönen Prozente wieder dahinrannen. Hab mich hinterher wie der letzte Depp gefühlt. Aber, wie Du schreibst: sehr lehrreich!
Viele Grüße,
bellfounder
Viele Grüße,
bellfounder
erb hälst, sind dir vermutlich die News nicht entgangen, oder?
Scchöner 20% Jump heute.
Gruss E.
Vision Sciences Announces Distribution Agreement with Medtronic Xomed Exclusive for ENT Products within the US and Canada
NATICK, Mass., Aug 7, 2003 /PRNewswire-FirstCall via COMTEX/ --
Vision-Sciences, Inc., (Nasdaq: VSCI) announced today that it has signed a
three-year distribution agreement with Medtronic Xomed, the ear, nose and throat
(ENT) business division of Medtronic, Inc. (NYSE: MDT). Under the agreement
Medtronic Xomed has become the exclusive distributor in the U.S. and Canada of
Vision Sciences' Slide-On(TM) EndoSheath(R) System products within the field of
otorhinolaryngology, including head and neck surgery. Medtronic Xomed will
market and sell Vision Sciences' ENT products, co-branded with both companies'
names and logos, through its dedicated sales force.
"We are extremely pleased to have Medtronic Xomed endorse the EndoSheath System
and become our marketing and distribution partner in the US and Canada for our
growing ENT product line. We expect these products to expand significantly the
use of the existing, widely installed base of diagnostic ENT endoscopes due to
their compatibility with existing models and because they also provide a
'delivery system' for procedures such as biopsy and sensory testing for
evaluation of swallowing disorders. We believe that the innovative EndoSheath
System, coupled with Medtronic Xomed's highly professional and established sales
and marketing forces, will result in effective market penetration for the
products. We look forward to a long and mutually rewarding relationship between
Scchöner 20% Jump heute.
Gruss E.
Vision Sciences Announces Distribution Agreement with Medtronic Xomed Exclusive for ENT Products within the US and Canada
NATICK, Mass., Aug 7, 2003 /PRNewswire-FirstCall via COMTEX/ --
Vision-Sciences, Inc., (Nasdaq: VSCI) announced today that it has signed a
three-year distribution agreement with Medtronic Xomed, the ear, nose and throat
(ENT) business division of Medtronic, Inc. (NYSE: MDT). Under the agreement
Medtronic Xomed has become the exclusive distributor in the U.S. and Canada of
Vision Sciences' Slide-On(TM) EndoSheath(R) System products within the field of
otorhinolaryngology, including head and neck surgery. Medtronic Xomed will
market and sell Vision Sciences' ENT products, co-branded with both companies'
names and logos, through its dedicated sales force.
"We are extremely pleased to have Medtronic Xomed endorse the EndoSheath System
and become our marketing and distribution partner in the US and Canada for our
growing ENT product line. We expect these products to expand significantly the
use of the existing, widely installed base of diagnostic ENT endoscopes due to
their compatibility with existing models and because they also provide a
'delivery system' for procedures such as biopsy and sensory testing for
evaluation of swallowing disorders. We believe that the innovative EndoSheath
System, coupled with Medtronic Xomed's highly professional and established sales
and marketing forces, will result in effective market penetration for the
products. We look forward to a long and mutually rewarding relationship between
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Gruss E.
LasikPlus to Offer Custom Lasik Procedures in All U.S. Markets; Company Reiterates 2003 Diluted EPS Guidance of $0.45 to $0.50
Tuesday, August 12, 2003 10:56 AM ET Printer-friendly version
CINCINNATI--(BUSINESS WIRE)--Aug. 12, 2003--LCA-Vision Inc. (Nasdaq: LCAV, news), a leading provider of laser vision correction services under the LasikPlus brand, today announced that it expects to complete the installation of wavefront analyzers to provide the LasikPlus custom laser vision correction procedure in all of its U.S markets by August 29, 2003. The custom Lasik procedure uses wavefront technology to measure specific imperfections in each individual's vision, thereby allowing for customized laser vision correction.
Custom Lasik equipment installations at LasikPlus facilities include the Alcon, Inc. (NYSE: ACL, news) LADARWave™ system, approved by the U.S. Food and Drug Administration (FDA) in October 2002, and the VISX, Incorporated (NYSE: EYE, news) WaveScan System, which received FDA approval in May 2003. LCA-Vision has been offering the custom Lasik procedure in its Canadian facilities since October 2001, and as of June 30, 2003, in five LasikPlus U.S. markets.
LasikPlus to Offer Custom Lasik Procedures in All U.S. Markets; Company Reiterates 2003 Diluted EPS Guidance of $0.45 to $0.50
Tuesday, August 12, 2003 10:56 AM ET Printer-friendly version
CINCINNATI--(BUSINESS WIRE)--Aug. 12, 2003--LCA-Vision Inc. (Nasdaq: LCAV, news), a leading provider of laser vision correction services under the LasikPlus brand, today announced that it expects to complete the installation of wavefront analyzers to provide the LasikPlus custom laser vision correction procedure in all of its U.S markets by August 29, 2003. The custom Lasik procedure uses wavefront technology to measure specific imperfections in each individual's vision, thereby allowing for customized laser vision correction.
Custom Lasik equipment installations at LasikPlus facilities include the Alcon, Inc. (NYSE: ACL, news) LADARWave™ system, approved by the U.S. Food and Drug Administration (FDA) in October 2002, and the VISX, Incorporated (NYSE: EYE, news) WaveScan System, which received FDA approval in May 2003. LCA-Vision has been offering the custom Lasik procedure in its Canadian facilities since October 2001, and as of June 30, 2003, in five LasikPlus U.S. markets.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Anzeige: Neue Kupfer-Entdeckung?
Explorationsprojekt mit viel Potenzial vor dem Durchbruch!
Nacht E.
About TLC Vision
TLC Vision Corporation is North America's premier eye care services company.
TLCVision enjoys a number of valuable assets including an affiliated network of
more than 12,500 optometrists and 1,000 ophthalmic surgeons, access to some of
the newest clinical technologies, proven patient education and marketing
programs, state-of-the art information systems, a strong operations management
culture and a number of well established corporate brands. The Company's common
shares trade on the NASDAQ National Market under the symbol 'TLCV' and on the
Toronto Stock Exchange under the symbol 'TLC'. Visit TLCVision's web site at
www.tlcv.com.
About TLC Vision
TLC Vision Corporation is North America's premier eye care services company.
TLCVision enjoys a number of valuable assets including an affiliated network of
more than 12,500 optometrists and 1,000 ophthalmic surgeons, access to some of
the newest clinical technologies, proven patient education and marketing
programs, state-of-the art information systems, a strong operations management
culture and a number of well established corporate brands. The Company's common
shares trade on the NASDAQ National Market under the symbol 'TLCV' and on the
Toronto Stock Exchange under the symbol 'TLC'. Visit TLCVision's web site at
www.tlcv.com.
Gruss E.
LCA-Vision (LCAV: news, chart, profile) surged more than 6 percent after the company said it expects 2004 EPS of 80-to-85 cents vs. 80 cents expected by Wall Street in a survey of analysts by Thomson First Call. The EPS figure would represent a jump of about 50 percent over 2003 levels. The Cincinnati-based laser vision surgery specialist pegged 2004 revenue at $110 million and said it expects to open up to eight vision centers in 2004.
LCA-Vision (LCAV: news, chart, profile) surged more than 6 percent after the company said it expects 2004 EPS of 80-to-85 cents vs. 80 cents expected by Wall Street in a survey of analysts by Thomson First Call. The EPS figure would represent a jump of about 50 percent over 2003 levels. The Cincinnati-based laser vision surgery specialist pegged 2004 revenue at $110 million and said it expects to open up to eight vision centers in 2004.
Gruss E.
Oder Visionen mit Icos Vision?
chart.bigcharts.com/bc3/quickchart/...90&mocktick=1&rand=1152"
Oder Visionen mit Icos Vision?
Gruss E.
ICOS Vision Systems Reports Financial Results for the First Quarter of 2004
HEVERLEE, Belgium, Apr 27, 2004 (BUSINESS WIRE) -- ICOS Vision Systems
Corporation NV (Nasdaq and Euronext: IVIS), a world leader in vision solutions,
today announced its financial results for the first quarter ended March 31,
2004.
Revenues for the three months ended March 31, 2004 were EUR 21.0 million,
representing an increase of approximately 40% compared to the fourth quarter
2003 revenues of EUR 15.0 million and a more than two-fold increase over the
prior year first quarter revenues of EUR 9.3 million. The company reported
operating income for the first quarter of 2004 of EUR 6.3 million, more than
double operating income of EUR 3.1 million for the fourth quarter of 2003 and a
significant increase from operating income of EUR 0.5 million for the first
quarter of 2003. Net income for the first quarter of 2004 was EUR 4.6 million or
44 Eurocents per share compared to net income of EUR 3.3 million for the fourth
quarter or 31 Eurocents per share and compared to net income of EUR 0.2 million
or 2 Eurocents per share for the first quarter of 2003. Cash and cash
equivalents stood at EUR 30.4 million at the end of the quarter with ICOS
generating EUR 1.0 million cash from operations, including changes in working
capital, during the quarter.
"The first quarter of 2004 marked the second consecutive quarter of 40%
sequential growth and the tenth consecutive quarter of sequentially increasing
revenue," said Anton DeProft, ICOS' president and chief executive officer. "Our
top line was driven by a continuing market upturn and strong ramp up of new
ICOS Vision Systems Reports Financial Results for the First Quarter of 2004
HEVERLEE, Belgium, Apr 27, 2004 (BUSINESS WIRE) -- ICOS Vision Systems
Corporation NV (Nasdaq and Euronext: IVIS), a world leader in vision solutions,
today announced its financial results for the first quarter ended March 31,
2004.
Revenues for the three months ended March 31, 2004 were EUR 21.0 million,
representing an increase of approximately 40% compared to the fourth quarter
2003 revenues of EUR 15.0 million and a more than two-fold increase over the
prior year first quarter revenues of EUR 9.3 million. The company reported
operating income for the first quarter of 2004 of EUR 6.3 million, more than
double operating income of EUR 3.1 million for the fourth quarter of 2003 and a
significant increase from operating income of EUR 0.5 million for the first
quarter of 2003. Net income for the first quarter of 2004 was EUR 4.6 million or
44 Eurocents per share compared to net income of EUR 3.3 million for the fourth
quarter or 31 Eurocents per share and compared to net income of EUR 0.2 million
or 2 Eurocents per share for the first quarter of 2003. Cash and cash
equivalents stood at EUR 30.4 million at the end of the quarter with ICOS
generating EUR 1.0 million cash from operations, including changes in working
capital, during the quarter.
"The first quarter of 2004 marked the second consecutive quarter of 40%
sequential growth and the tenth consecutive quarter of sequentially increasing
revenue," said Anton DeProft, ICOS' president and chief executive officer. "Our
top line was driven by a continuing market upturn and strong ramp up of new
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Gruss E.
LCA-Vision 1Q Same-Store Sales Growth 48% >LCAV
CINCINNATI (Dow Jones)--LCA-Vision Inc.(NASDAQ-NMS:LCAV) (LCAV) saw first-quarter income jump more than six-fold, helped by 48% same-store sales growth at its LasikPlus vision centers and a hefty income tax benefit.
In a press release Tuesday, LCA-Vision(NASDAQ-NMS:LCAV) reported earnings of $12.7 million, or 93 cents a share, up from $1.8 million, or 16 cents a share, last year.
Excluding a gain of $5.9 million on the reversal of a portion of the valuation allowance on deferred tax assets, the company earned $6.8 million, or 50 cents a share.
Revenue in the quarter climbed about 58% to $31.7 million from $20 million last year, as procedure volume rose 43% to 24,270 procedures performed, while revenue per procedure increased 11% to $1,304.
Based on this performance, the company raised 2004 earnings guidance to between $1.55 and $1.65 a share, including the first-quarter tax gain. The company previously put 2004 earnings at 90 cents to 95 cents a share.
Analysts, on average, expect the company to report earnings of $1.04 a share for fiscal 2004, based on a Thomson First Call survey. LCA-Vision(NASDAQ-NMS:LCAV) reported earnings of 66 cents a share for 2003.
The company also projected pretax income of $16.6 million to $18.2 million in 2004 on revenue of between $115 million and $117 million; the latter is an improvement from the prior $110 million view. Revenue for 2003 totaled $81.4 million.
LCA-Vision Inc.(NASDAQ-NMS:LCAV)
§
1st Quar March 31:
2004 2003
Sales $31,650,000 $19,982,000
Net income a 12,729,000 1,757,000
Avg shrs (diluted) 13,751,000 10,744,000
Shr earns
Net income a .93 .16
Figures in parentheses are losses.
LCA-Vision 1Q Same-Store Sales Growth 48% >LCAV
CINCINNATI (Dow Jones)--LCA-Vision Inc.(NASDAQ-NMS:LCAV) (LCAV) saw first-quarter income jump more than six-fold, helped by 48% same-store sales growth at its LasikPlus vision centers and a hefty income tax benefit.
In a press release Tuesday, LCA-Vision(NASDAQ-NMS:LCAV) reported earnings of $12.7 million, or 93 cents a share, up from $1.8 million, or 16 cents a share, last year.
Excluding a gain of $5.9 million on the reversal of a portion of the valuation allowance on deferred tax assets, the company earned $6.8 million, or 50 cents a share.
Revenue in the quarter climbed about 58% to $31.7 million from $20 million last year, as procedure volume rose 43% to 24,270 procedures performed, while revenue per procedure increased 11% to $1,304.
Based on this performance, the company raised 2004 earnings guidance to between $1.55 and $1.65 a share, including the first-quarter tax gain. The company previously put 2004 earnings at 90 cents to 95 cents a share.
Analysts, on average, expect the company to report earnings of $1.04 a share for fiscal 2004, based on a Thomson First Call survey. LCA-Vision(NASDAQ-NMS:LCAV) reported earnings of 66 cents a share for 2003.
The company also projected pretax income of $16.6 million to $18.2 million in 2004 on revenue of between $115 million and $117 million; the latter is an improvement from the prior $110 million view. Revenue for 2003 totaled $81.4 million.
LCA-Vision Inc.(NASDAQ-NMS:LCAV)
§
1st Quar March 31:
2004 2003
Sales $31,650,000 $19,982,000
Net income a 12,729,000 1,757,000
Avg shrs (diluted) 13,751,000 10,744,000
Shr earns
Net income a .93 .16
Figures in parentheses are losses.
Es gibt keine neuen Beiträge.
Ich:
